C12N 2770/24041
Use of virus, viral particle or viral elements as a vector
C12N2770/24041 (Use of virus, viral particle or viral elements as a vector) appears on 5 US grants and 11 published applications in this corpus.
Search patents in C12N- Granted patents
- 5
- Published applications
- 11
- Assignees
- 9
- Inventors
- 20
- Latest grant
- 11 Oct 2022
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 2 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 1 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 2 |
| 2020 | 0 | 1 |
| 2021 | 1 | 0 |
| 2022 | 2 | 0 |
| 2023 | 0 | 2 |
| 2024 | 0 | 1 |
| 2025 | 0 | 1 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2770/24043Viral genome or elements thereof as genetic vectorIndexing code3
- C12N 2770/24044Chimeric viral vector comprising heterologous viral elements for production of another viralIndexing code1
- C12N 2770/24042Virus or viral particle as vehicleIndexing code0
- C12N 2770/24045Special targeting system for viral vectorsIndexing code0
Recent patents
- Dengue vaccine unit dose and administration thereof11 Oct 2022US 11,464,815 B2Takeda Vaccines, Inc.
- Methods of treating cancer15 Mar 2022US 11,273,170 B2Ascend Biopharmaceuticals Ltd
- Zika as a cell penetrating peptide for delivery to the brain20 Jul 2021US 11,066,448 B2Buck Institute for Research on Aging
- Flavivirus recombinant poxvirus vaccine28 Apr 1998US 5,744,140 AVirgenetics Corporation
- Flavivirus recombinant poxvirus immunological composition28 Apr 1998US 5,744,141 AVirogenetics Corporation
- Dengue vaccine unit dose and administration thereof25 Jun 2026US 2026/0174812 A1Takeda Vaccines, Inc.
- Next generation mrna vaccines20 Mar 2025US 2025/0090648 A1FuTr Bio Ltda.
- E protein-mutated west nile virus used as liveattenuated vaccine and oncolytic drug for cancer therapy17 Oct 2024US 2024/0342265 A1SICHUAN ANCOCARE BIOPHARMACEUTICAL, Ltd.
- Dengue vaccine unit dose and administration thereof27 Jul 2023US 2023/0233628 A1Takeda Vaccines, Inc.
- Method to treat hepatoma with dengue viruses and a method to kill hepatocellular carcinoma tissues27 Jul 2023US 2023/0233629 A1Syi Biotechnology Co., Ltd.
Most cited
By later US patents